Citations

Clear

58 citation(s) found for "Robles, R".

Factors associated with cancer treatment delay: a protocol for a systematic review and meta-analysis
Morrill, Kristin E. , Robles‐Morales, Rogelio , Lopez‐Pentecost, Melissa , Portilla, Raigam J Martínez, Skiba, Meghan B. , Riall, Taylor S. , Austin, Jessica D. , Hirschey, Rachel , Jacobs, Elizabeth T. , Spotleson, Lena, Skiba, Meghan B , Austin, Jessica D , Hanna, Timothy P , Portilla, Raigam Jafet Martínez , Saleh, Ahlam A.

Mayo Clinic

BMJ Open | June 29, 2022 | Volume: 12 | Issue: 6 | Pages: e061121

10.1136/bmjopen-2022-061121 | PMID 35768104 Get It

Introduction Treatment delays are significantly associated with increased mortality risk among adult cancer patients; however, factors associated with these delays have not been robustly evaluated. This review and meta-analysis will evaluate factors associated with treatment delays among patients with five common cancers. Methods and analysis Scientific databases including Ovid MEDLINE, Elsevier Embase, EBSCOhost CINAHL Plus Full Text, Elsevier Scopus and ProQuest Dissertations and Theses Global will be searched to identify relevant articles published between January 2000 and October 2021. Research articles published in the USA evaluating factors associated with treatment delay among breast, lung, prostate, cervical or colorectal adult cancer patients will be included. The primary outcome of the meta-analysis will be the pooled adjusted and unadjusted odds of treatment delay for patient, disease, provider and system-level factors defined according to specified time intervals. The secondary outcomes will be mean or median treatment delay for each cancer site according to first treatment and the influence of factors on the pooled mean treatment delay for each cancer site (via meta-regression analyses). Results from qualitative and mixed-methods studies will be narratively synthesised. Three reviewers will independently screen records generated from the search and two reviewers will independently extract data following a consensus agreement. Statistical heterogeneity will be assessed with a standard I 2 test and funnel plots will be conducted to evaluate publication bias. Risk of bias will be assessed independently by two authors using validated tools according to the article’s study design. Ethics and dissemination Formal ethical approval is not required because the work is being carried out on publicly accessible studies. The findings of this review will be disseminated through a peer-reviewed scientific journal, academic conferences, social media, and key stakeholders. PROSPERO registration number CRD42021293131.
Letter by Natale et al Regarding Article, “Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial”
Natale, Andrea , Kar, Saibal , Holmes, David R. , Holmes, David R , Kar, Saibal , Natale, Andrea

Mayo Clinic

Circulation | April 25, 2022 | Volume: 145 | Issue: 17 | Pages: No page available

10.1161/circulationaha.121.057567 | PMID 35467955 Get It

Abstract 23085: 30-Day Outcomes of Transseptal Transcatheter Mitral Valve Replacement for Failed Surgical Bioprostheses (Mitral Valve-in-Valve): The MITRAL Trial (Mitral Implantation of TRAnscatheter vaLves)
Salinger, Michael H., Kodali, Susheel , Satler, Lowell F. , Inglessis, Ignacio, Eleid, Mackram F. , Meduri, Christopher, Rajagopal, Vivek , Reisman, Mark, Aldea, Gabriel S. , Eng, Marvin H. , Waksman, Ron , Pichard, Augusto D., Palacios, Igor F. , Russell, Hyde M., Saucedo, Jorge , Makkar, Raj , Rihal, Charanjit S. , Leon, Martin B. , Feldman, Ted , Guerrero, Mayra , Pursnani, Amit , Wang, Dee Dee , George, Isaac , Hahn, Rebecca T , Kar, Saibal , O’Neill, William W. , Rihal, Charanjit S.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 136 | Issue: suppl_1 | Pages: No page available

10.1161/circ.136.suppl_1.23085 Get It

Introduction: Transcatheter mitral valve replacement (TMVR) using aortic transcatheter heart valves (THV) is developing as an alternative to surgery for patients with severely degenerated mitral valve (MV) bioprostheses. Retrospective self-reported registries have collected outcomes on these TMVR procedures in the STS/ACC Transcatheter Valve Therapy Registry and in the Valve-in-Valve International Database. Most reported TMVR procedures for failed surgical bioprostheses have been performed using a transapical access approach. A prospective comprehensive evaluation of mitral Valve-in-Valve (VIV) outcomes, including transseptal access has not previously been conducted. Objectives: To evaluate in-hospital and 30-day clinical outcomes of transseptal mitral VIV with SAPIEN 3 THV in patients with very high surgical risk. Methods: Prospective enrollment of very high surgical risk patients with symptomatic severely degenerated MV surgical bioprostheses in 30 patients at 15 sites in the U.S. Candidates were assessed by a case review committee prior to approval. Baseline qualifying echocardiograms and cardiac CT studies were analyzed by independent core labs. Echocardiograms, cardiac CT studies and neurology evaluations were also performed after mitral VIV procedures. Clinical events were adjudicated by a clinical events committee and safety was monitored by a data safety monitoring board. Results: 26 patients have been enrolled between July 2016 and June 2017. Mean age was 83 years, 62% female, mean STS score was 10% and 62% were in New York Heart Association class III or IV. Transseptal access was used in all procedures. Technical success was achieved in all patients and there was no in-hospital mortality. There was no 30-day cardiovascular mortality and 4% (1 patient) 30-day all-cause mortality (1 patient died of asphyxia on day 29 after choking on pills at home), which was lower than the 30-day mortality in the TVT registry (9%). Detailed procedural, in-hospital and 30-day outcomes will be presented on the complete cohort of 30 patients. Conclusions: In patients without surgical alternatives, transseptal mitral ViV procedures in failed surgical bioprostheses are associated with high technical and procedural success and low 30-day mortality.
Abstract 23079: Clinical Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Mitral Valve-in-Valve) and Surgical Rings (Mitral Valve-in-Ring) in the United States: Data From the STS/ACC/TVT Registry
Wang, Dee Dee D, Vemulapalli, Sreenkanth, Xiang, Katelyn, Salinger, Michael H., Eleid, Mackram F. , Kodali, Susheel , Fang, Kenith, Coylewright, Megan , Shah, Pinak , Thourani, Vinod H. , Babaliaros, Vasilis , Tommaso, Carl L. , Saucedo, Jorge , Makkar, Raj , Leon, Martin B. , Rihal, Charanjit S. , Feldman, Ted , Guerrero, Mayra , Greenbaum, Adam B. , George, Isaac , Whisenant, Brian K. , Pershad, Ashish , Shah, Pinak , Kar, Saibal , Rihal, Charanjit S. , O’Neill, William W.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 136 | Issue: suppl_1 | Pages: No page available

10.1161/circ.136.suppl_1.23079 Get It

Introduction: Transcatheter mitral valve replacement (TMVR) using aortic transcatheter heart valves (THV) is developing as an alternative to surgery for patients with severe mitral valve disease due to degenerated mitral bioprostheses or failed surgical rings who are poor surgical candidates. Outcomes of off-label procedures in the United States are being collected in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. A comprehensive analysis of mitral Valve-in-Valve (VIV) versus Valve-in-Ring (VIR) outcomes has not previously been performed. Objectives: To evaluate in-hospital and 30-day clinical outcomes of mitral VIV and VIR procedures in the United States. Methods: Retrospective analysis of data from the STS/ACC TVT Registry on patients who underwent mitral VIV or VIR procedures. Results: 587 patients underwent TMVR VIV (n=494) or VIR (n=93) procedures between January 2013 and December 2016 at 144 hospitals. Median age was 76 (VIV) and 73 (VIR) years, (p=0.024), 60.9% (VIV) and 44.1% (VIR) were female (p=0.003), median left ventricular ejection fraction was 55% in VIV and 50% in VIR (p <0.001), and median STS score was 10.5% (VIV) and 9.2% (VIR), p=0.131. Transseptal access was utilized in 35% VIV and 46.2% VIR procedures, p=0.081. Procedural success was achieved in 74.4% of VIV and 57.8%VIR (p=0.239). Left ventricular outflow tract (LVOT) obstruction was more common in VIR (5.4%) vs VIV (0.06%), p=0.003. Post-procedure median mean mitral valve gradient was 4mmHg in both groups. 95.7% of VIV and 86% of VIR patients had post-procedure mitral regurgitation ≤1(+), p<0.001. In-hospital mortality was 6.9% for VIV and 9.7% for VIR (p=0.343). 30-day mortality was 9% for VIV and 12% for VIR (p=0.387). At 30-day follow up, 85.6% of VIV and 77.7% of VIR patients were in New York Heart Association class I or II (p=0.398). Conclusions: TMVR VIV and VIR using aortic transcatheter heart valves in high surgical risk patients are associated with similar in-hospital and 30-day mortality and symptom benefit. LVOT obstruction post-TMVR and residual mitral regurgitation ≥2 (+) were more frequent in VIR procedures. The long-term effect of these procedures is not known and requires further evaluation.
Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients
Johnstone, Jennie , Meade, Maureen O. , Lauzier, François, Duan, Erick , Dionne, Joanna C. , Heels‐Ansdell, Diane , Thabane, Lehana , Lamarche, Daphnée , Zytaruk, Nicole , Mehta, Sangeeta , Dodek, Peter , McIntyre, Lauralyn , Karachi, Tim , Henderson, William R. , Wood, Gordon , Ovakim, Daniel , Herridge, Margaret S. , Granton, John , Wilcox, M. Elizabeth , Goffi, Alberto , Niven, Daniel J. , Lamontagne, François , D’Aragon, Frédérick , St.-Arnaud, Charles, Ball, Ian, Nagpal, Dave , Girard, Martin , Aslanian, Pierre, Charbonney, Emmanuel , Sligl, Wendy , Adhikari, Neill K. J. , Marquis, François, Archambault, Patrick , Khwaja, Kosar , Kristof, Arnold S. , Kutsogiannis, James, Paunovic, Bojan, Reeve, Brenda , Lellouche, François , Hosek, Paul, Tsang, Jennifer , Binnie, Alexandra , Trop, Sébastien, Loubani, Osama , Hall, Richard , Cirone, Robert, Reynolds, Steve, Lysecki, Paul, Golan, Eyal, Cartin‐Ceba, Rodrigo , Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Wallace, Christine, Sobhi, Gita, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Centoanti, John, Lamarche, Daphne, Laupacis, Andreas, Roberts, Robin, Brun‐Buisson, Christian , Reynolds, Steve, Willems, Sue, Sekhon, Tina , Dodek, Peter, Ayas, Najib , Agda, Maria, Alcuaz, Victoria, Ashley, Betty-Jean, Brewer, Kelsey, Palmer, Janice L. , Brown, Glen, Pavan, Mara, Greisdale, Donald, Foster, Denise , Logie, Suzie, Yip, Judy, Auld, F. C., Carney, Gayle, FLEMING, R.Y. Declan, Good, Jennifer, Manhas, Mandeep, Boyd, Karin, Dheere, Jane, Stelfox, Tom, Couillard, Philippe , Doig, Christopher J. , Booth, Joshua , Codan, Cassidy, Ruddell, Stacy, Cameron, C. Blake, Edison, Rhonda, Mina, Breanna, Berthiaume, Luc , Gaudet, Jonathan, Kutsiogiannis, Jim, Chowdhury, Raiyan, Davidow, Jon, Johnston, Curt, Johnston, Richard , Macala, Kim, Marcushamer, Sam, Markland, D., Matheson, Doug, Payton-Gay, Damian, Zygun, David, Hewer, Tayne, Thompson, Pat, Ge, Maggie, Hall, Janny, Matenchuk, Sharon, Baig, Nadia, McCoshen, Lorena, Alexandropoulos, Katrina, Bain, Sherri, Brandt, Michelle , Constable, Cathy, Douglas, K., Maharaj, Shaleen, Travers, Sabrina, Zarychanski, Ryan, Lys, Justin, Marten, Nicole, Bhairo, Audrey, Ferenes, Halyna, Kozak, Beata, Verrier, Debra, McLaughlin, Dawn-Lee, Blouw, Marcus , Smith, Heather , Gutieror, Oliver, Wingfield, Sherri Lynn, Boyle, M A, Hrabi, Debbie, MacDonald, Chantal, Bento, Karen, Davis, Megan , Dechert, William , Longo, Barbara, Mullen, Courtney, Skrzpek, Elysia, Wierenga, Laurenne, Abuzaiter, Wesam, Amorim, Lynda, Bauer, Rosemarie, Damota, Rachel, Ho, Hoang, Macdougall, Nicole, Thornewell, Mary, Tran, Lara , Visocchi, Jennifer, Hosek, Paul, Plaxton, Bill, Armstong, Catherine, Ellis, Janelle, Fisk, Kayla, Gabnouri, Melissa, Gordon, Emilie, Haegens, Rebecca, Halford, Lisa, Hillis, Brooklyn, Jesso, Rebecca, McLaren, Jennifer , McMillan, Elliot, Pelkmans, Mariska, Rekman, Matthew, Sinkovitis, Sylvia, Truong, Monica, White, Michelle C. , Bates, Noah, Bryden-Cromwell, Susan, Cameron, Colleen, Deen, A. Gamal El, DiGiovanni, Sheri, Foss, Anders, Lee, E. H. , MacGregor, Heidi, Galbraith, Esther, McArthur, Robyn, Mcgregor, J., Miller, Keith R. , Morris, Sharon, Parker, Shelley, Smith, Candice A. , Stoglow, Joanna, Tung, Jennifer , Vos, Melissa , Hand, Lori, Klotz, Lisa, Sabev, Alexandra, Savija, Nevena , Guyatt, Paige, Cosentino, Deanna, Lourenco, Diane, Misina, Julie, Berlingieri, Joseph, Skitch, Steven , Campbell, Tracy , Basheer, Hala, Bruder, Kathy, Cheng, Jane, Qureshi, Kaiser, Infantino, C. A. González, Karachi, Timothy, Alghuroba, Mashari, Khaled, Alia , Millen, Tina, Vaisler, Ryan, Biljan, Maya, Cosentino, Deane, Marriott, Brittany, Muscedere, John, Boyd, Gordon, D`Arsigny, Christine, Drover, John, Erb, Jason , Parker, Chris M., Sibley, Stephanie , Boyd, Tracy, Georgescu, Ilinca, Hunt, Miranda , Muscedere, D., Baker, Cathy, Engel, Jennifer, Fleming, Jennifer , Roderick, Lisa, Silk, Shelley, Spencer, Marcy, Tryon, Michelle, Nagpal, Dave, Ball, Ian, Sharpe, Michael D., Bentall, Tracey, Sturt-Smith, Jessica, Ellis, T.M., Muylaert, Mindy, Paczkowski, Cindy, Campbell, Eileen, Imervoski, Susie, Ovsenek, Athena, Rondinelli, Rebecca, Longfield, Teresa, Moyer, Amy, Norris, F. H., Sumpton, Janice, Teterycz, Karina, Lapinsky, Stephen E. , Munshi, Laveena, Brown, Maedean, Giacomino, Brittany, Jakab, Marnie, Kraguiljac, Alan, Shah, Sumesh, Tamberg, E., Cheng, Doret, Han, Andrew , Leung, Holly, Mantas, Ioanna, Rodrigues, Hilary, Wyllie, Andew, Carmargo, Mercedes, Richter, Beverly, Caporuscio, Rita, Falvo, Rachel Kressner, Fleming, Dimitra, Maxwell, Carmelina, Plantic, Karmen, McIntyre, Lauralyn, Pagliarello, Giuseppe, D`Egidio, Gianni, English, Shane, Hartwick, Mike, Hooper, Jonathan C., Kubelik, D., Meggison, Hilary , Patel, Rakesh , Po, Joseph, Rosenberg, Erin, Gomes, Brigette, Leclair, Lianne, Porteous, Rebecca , Reddie, Shawna, Watpool, Irene , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, Richard, Susanne, Weir, Sherry, Cardinal, Pierre , Jones, Gwynne, Microys, Sherissa, Sarti, Aimee , Seely, Andrew , Acres, Shelley, Mietitis, Sydney, Montroy, Kaitlyn, Aikens, Wendy, Dugal, Anne-Marie, Soth, Mark, Alhazanni, Waleed, Clarke, France, Copland, Mary, Hoad, Neala, Sheers, M., Takaoka, Alyson, Zytaruk, Nicole, Connolly, Christa, Davis, Denise, Gallinas, Tracy, Lee-Yoo, Jean, Lukinuk, Connie, Musielak, Leia, Pavunkovic, Nancy, Pelayo, Joy, Phillips, Kaitlyn , Pracsovics, Catherine, Raimondo, Julia, Stankus, Vida, Wright, Angela, Young, Crystal , Cirrone, Rob, Kavikondala, Kanthi, Pellerin, Axelle, Tomat, Laura, Carter, Jeff , Jani, J., Yaets, Brendan, Hodder, Jennifer, Khalid, Imrana, Lee, Julie , Salway, Kurtis D., Sandhu, Gyan, Santos, Marlene, Smith, Orla, Wang, Melissa, Dewhurst, Norman, Dowbenka, Ann, Kosinski, Ann, Parsons, Laura, Proceviat, J, Ramonas, Gitana, Yuen, Mae, Amaral, Andre , Fowler, Rob, Scales, Damon C. , Marinoff, Nicole, Pérez, Adic, Wang, Jane , Hatzifilalithis, Katrina, Iazzetta, John, Kolos, Chrys, Quinton, Ingrid, Herridge, Margaret, Archer, Jaimie, Fraser, Brooke , Geen-Smith, Cheryl, Matté, Andrea, Robles, Priscilla, Urrea, Cristian, Ascroft, Jane, Haji, Fatima , Ming, Jie , Suen, Matthew , Walid, Muhammad, Westlund, Jill M., McCredie, Victoria , Wilcox, Elizabeth , Farías, Paulina , Kosky, Barbara, Pugliese, Christina, Stenyk, Lia, Walczak, Karolina, Ae, Kyung, Kaur, Rajvinder , Lui, Jane , Mateo, Sophia, Pham, Nga, Heslegrave, Ronald J. , Panchbhaya, Zaynab, Sharman, Kim, Goel, Rakhi, Kozluk, Kim, Labelle, Julianne, Marsonia, Hina, Scott, Cecillia, Aslanian, P., Bélisle, Sylvain, Denault, André , Guimond, Jean‐Gilles, Halwagi, Antoine, Hebert, Paul L. , Kolan, Christopher, Mancebo, Jordi , Robillard, Nicholas , Benettaib, Fatna, Boumahni, Dounia, Caporuscio, Casey Bourdeau, Cantin, M, Côté-Gravel, Virginy, Ghamraoui, Ali, Lebrasseur, Martine, Courville, Lancelot Legendre, Lorio, S., Madrid, Maria Trinidad, Poitras, Nicole, Rigal, Romain, Salamé, Maya, Tran, V.K., Bacon, Katie, Boudreau, Nathalie , Carvajal, Cecilia, Gauthier, Lyne, Gendron, Julie, Jean, Karine, Laforest, Louise, Lembo, Antonietta, Lim, S. H., Pagé, France, Pelletier, L, Rodrigue, Marie-Christine, Bellemare, Jean-François, Bordeleau, Simon, Drouin, Christine, Duhaime, Benoit, Laberge, Ann, Lechance, Philippe, Deblois, Estel, Dionne, Maude, Lavoie, Lise, Michel, Isabelle, Pépin, A., Poulin, S., Anctil, Sarah, Marchand, Louis-Étienne , Roy, Robin, St-Arnaud, Charles , Quiroz, Héctor, Bérard, Dominique, Leclair, Marc-André, Bolduc, Virginie, Carbonneau, Élaine, Marchand, Joannie, Masse, Marie-Hélène , Cloutier, Sylvie , Guay, M, Morin, Line, Nicolson, J. T., Paquette, Isabelle, Théberge, France, Lamarche, Yoan , LeGuillan, Soazig, Serri, Karim , Verdant, Colin , Beaulieu, Yanick, Bellemare, Patrick, Rico, Philippe, Bernard, Françis , Giasson, Marc, Brunette, Véronique, Cavayas, Alexandros, Lévesque, Émilie, Labikova, Halina, Palacios, Julia , Langlois, Marie-Ève, Williams, Virginie, Nguyễn, Thùy Anh , Phaneuf, Valérie, Wang, Han Tin, Toupin, Francis, Ahern, Stéphane P., Laufer, Brian, Brosseau, Marc, Dul, Pauline, Harvey, Johanne, Inthanavong, Lotthida, Tassy, Danaë, Assayag, Helen, Bachand, M., Bétournay, Marysa, Daoust, Karine, Goyette, Kristine, Lessard, Ariane, Quach, Marceline, Barriault, Danny, Bellemare, David, Boivin, Anick, Breton, S., Cloutier, Ève, Daigle, Marjorie, Delisle-Thibeault, Charles, Giannakouros, Panagiota, Grenier, Stéphanie, Guilbault, Gabrielle, Léger, Caroline, Trembley, Marie-Claude, Gaudreau, Julie, Grégoire, Claire, Labbé, Véronique, Laprise-Rochette, Ariane, Ouellet, Caroline, Samson, Mélanie , Simoneau, Marie-David, Tourcotte, Virginie, Tran, Tuong-Vi, Lellouche, François, Sia, Ying Tung, Simon, Mathieu, Bouchard, Pierre-Alexandre, Lizotte, Patricia, Châteauvert, Nathalie, Grenier, T, Khwaja, Kosar, Deckelbaum, Dan, Gursahaney, Ash, Hornstein, David, Jayaraman, Dev , Razek, Tarek , Salasidis, Robert, Zanelli, Patrizia, Alam, Norine , Doerksen, Tonia, Matte, Gilbert, Robert, Marie‐France, Goldberg, Peter, Hatzakorzian, Roupen , Shahin, Jason , Qureshi, Salman, Campisi, Josie, Botan, Vasilica, Capilnean, Anissa, Corey, A. E., Gagné, Annick, Mian, J N, Normandin, Kathleen, Hall, Rick , Green, Robert, Gillis, Diana, Julien, Lisa, Magennis, Laura, Mitterer, Tamara, Arsenault, Joanna, Bruce-Payne, Kim, Gallant, Patti, Oeckler, Richard A. , Anderson, Brenda J., Liedl, Lavonne M., Meade, Laurie, Weist, Sueanne, Bartoo, Anna, Bauer, Debbie, Brickley, Vince, Bridges, S. Louis , Brunn, G.J., Eickstaedt, Jennifer E., Bergerson, Jill, Showalter, Sandy, Manley, Melissa, Taylor, Robert, Cryton, Margaret, Fowler, K. T., Krause, Katie, O`Brien, Jackie, Tow, Marianne, Ma, John, Moore, Kaitlin MS, Al‐Dawood, Abdulaziz, Tlayjeh, Haytham , Ghanem, Alaaeldien, Hassanien, Ahmad, Sharkawi, Ashraf El, Humaid, Felwa Bin, Alanizi, Hala, Alanizy, Nadyah, Bogami, Njoud Al, Muhaidib, Mohammed, Gramish, Jawaher , Alsomali, Randa, Devera, Nora, Villafranca, M.C. Muñoz, Fowler, Robert , Thabane, Lehana , Lauzier, François, Marshall, John C. , Arabi, Yaseen M. , Surette, M G , English, Shane , Rochwerg, Bram , Stelfox, Henry T. , Muscedere, John , Ball, Ian, Williamson, David R. , Friedrich, Jan O. , Kutsogiannis, Demetrios James , Zarychanski, Ryan , Taylor, Robert, Cook, Deborah, Group, Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT) Investigators and the Canadian Critical Care Trials, Johnstone, Jennie, Lauzier, François, Cook, Deborah, Oczkowski, Simon J. W. , Bowdish, Dawn M. E. , Reynolds, Steve, Dodek, Peter, Ashley, Betty Jean, Palmer, Janice, Sekhon, Mypinder S. , Auld, Fiona, Fleming, R.Y.Declan, Stelfox, Tom, Parhar, Ken Kuljit S. , Cameron, Candice, Martin, Anne , Thompson, Pat, Bagshaw, Sean M. , Brandt, Michelle, Douglas, Kari, Zarychanski, Ryan, Valente, Maria, Olafson, Kendiss P. , Smith, Heather, Abuzaiter, Wesam, Hosek, Paul, Fisk, Kayla M., McLaren, Jennifer, White, Michelle, Deen, Aminah, Lee, Esther, McGregor, Julie, Miller, Keith, Morris, Sharon, Vos, Melissa, Belley‐Côté, Emilie P. , Shaikh, Sameer, Qureshi, Kaiser, Muscedere, John, D`Arsigny, Christine, Maslove, David M. , Fleming, Jennifer, Spencer, Marcy, Nagpal, Dave, Ball, Ian, Bosma, Karen J. , Alexander, Michelle, Norris, Faith, Munshi, Laveena , Grewal, Gagan , McIntyre, Lauralyn, D`Egidio, Gianni, English, Shane, Hooper, Jonathan, Kyeremanteng, Kwadwo , Neilipovitz, David , Cox, Marianne, Fraser, Kathy, Kuhn, Jennifer, MacLeod, Rob , Rose, Dawn, Kim, John S. , Beinum, Amanda van , Fetzer, Susan, Clarke, France J. , Sheers, Melissa, Zytaruk, Nicole, Davis, Denise, Eaton, Catherine, Lukinuk, Connie, Wright, Angela, Khalid, Imrana, Lee, Julie, Lee, Yoon Min , Cuthbertson, Brian H. , Kaur, Navjot , Herridge, Margaret, Chen, Daniel Tzu-Hsuan , Haji, Fatima, Ming, Jie, Farias, Paulina, Kaur, Rajvinder, Pham, Tam Thi , Goel, Rakhi, Carrier, François Martin , Chassé, Michaël , Hébert, Paul, Kolan, Christophe , Boumahni, Dounia, Ghamraoui, Ali, Lebrasseur, Martine, Lorio, Stéphanie, Laforest, Louise, Lim, Sothun, Morrissette, Jennifer, Pagé, France, Dionne, Maude, Michel, Isabelle, Pépin, Alexandre, Poulin, Sandrine, Cloutier, Sylvie, Nicolson, Jessie, Paquette, Isabelle, Harvey, Johanne, Inthanavong, Lotthida, Daoust, Karine, Turgeon, Alexis F , Boivin, Anick, Breton, Sarah-Judith, Ouellet, Catherine, Grégoire, Claire, Samson, Mélanie, Lellouche, François, Khwaja, Kosar, Grushka, Jeremy Richard , Garcia, Laura, Magder, Sheldon A. , Corey, Alyssa, Mian, Jasmine, Hall, Rick, Green, Robert, Gillis, Diana, Anderson, Brenda, Brunn, Greg, Stern, Erin, Taylor, Robert, Fowler, Kim, Krause, Katie, Moore, Kaitlin , Ghanem, Alaaeldien, Hegazy, Mohamed I. , Villafranca, Marjane

Mayo Clinic

JAMA | September 21, 2021 | Volume: 326 | Issue: 11 | Pages: 1024

10.1001/jama.2021.13355 | PMID 34546300 Get It

Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers
Breuer, Eva , Mizuno, Takashi , Bartsch, F. , Ratti, Francesca , Benzing, Christian , Ammar-Khodja, Noémie, Sugiura, Teiichi , Takayashiki, Tsukasa , Hessheimer, Amelia J. , Kim, Hyung Sun , Ahn, Keun Soo , Wong, Tiffany , D’Silva, Mizelle , Koerkamp, Bas Groot , Jeddou, Heithem , Ponthaud, Charles de , Ismail, Warsan, Nooijen, Lynn E. , Hidalgo-Salinas, Camila, Wagner, Kim C. , Gunasekaran, Ganesh , Higuchi, Ryota , Gleisner, Ana , Shwaartz, Chaya , Schulick, Richard D. , Yamamoto, Masakazu , Schwartz, Myron , Oldhafer, Karl J. , Prachalias, Andreas , Fusai, Giuseppe , Erdmann, Joris I. , Line, Pål‐Dag , Smoot, Rory L. , Robles, R , Boudjéma, Karim , Polak, Wojciech G. , Neumann, Ulf P. , Lo, Chung‐Mau, Kang, Koo Jeong , Park, Joon Seong , Fondevila, Constantino , Uesaka, Katsuhiko , Pratschke, Johann , Aldrighetti, Luca , Oliveira, Michelle, Lang, Hauke , Nagino, Masato , Clavien, Pierre‐Alain , Yonkus, Jennifer A. , Line, Pål Dag , Smoot, Rory L , Aldrighetti, Luca , Erdmann, Joris I , Polak, Wojciech G , Wong, Tiffany C L , De Ponthaud, Charles , Groot Koerkamp, Bas , Ratti, Francesca , Mueller, Matteo , Kim, Hyung Sun, Ruzzenente, Andrea , Ahn, Keun Soo, Wong, Tiffany, Bednarsch, Jan , Jeddou, Heithem, Lopez-Lopez, Víctor; https://orcid.org/0000-0003-1718-3352, Kontis, Elissaios A. , Higuchi, Ryota, al, et, Schulick, Richard D., Yamamoto, Masakazu, Noji, Takehiro , Hirano, Satoshi, Schwartz, Myron, Oldhafer, Karl J., Fusai, Giuseppe K., Soubrane, Olivier , Polak, Wojciech G.; id_orcid 0000-0002-3096-4893, Han, Ho Seong, Neumann, Ulf P., Lo, Chung Mau , Guglielmi, Alfredo , Ohtsuka, Masayuki , Adam, René, Pratschke, Johann, Oliveira, Michelle L. De, Gores, Gregory J.

Mayo Clinic

Annals of Surgery | August 2, 2021 | Volume: 274 | Issue: 5 | Pages: 780-788

10.1097/sla.0000000000005103 | PMID 34334638 Get It

Objective: The aim of this study was to define robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons. Background: Despite ongoing efforts, postoperative mortality and morbidity remains high after complex liver surgery for PHC. Benchmark data of best achievable results in surgical PHC treatment are however still lacking. Methods: This study analyzed consecutive patients undergoing major liver surgery for PHC in 24 high-volume centers in 3 continents over the recent 5-year period (2014–2018) with a minimum follow-up of 1 year in each patient. Benchmark patients were those operated at high-volume centers (≥50 cases during the study period) without the need for vascular reconstruction due to tumor invasion, or the presence of significant co-morbidities such as severe obesity (body mass index ≥35), diabetes, or cardiovascular diseases. Benchmark cutoff values were derived from the 75th or 25th percentile of the median values of all benchmark centers. Results: Seven hundred eight (39%) of a total of 1829 consecutive patients qualified as benchmark cases. Benchmark cut-offs included: R0 resection ≥57%, postoperative liver failure (International Study Group of Liver Surgery): ≤35%; in-hospital and 3-month mortality rates ≤8% and ≤13%, respectively; 3-month grade 3 complications and the CCI: ≤70% and ≤30.5, respectively; bile leak-rate: ≤47% and 5-year overall survival of ≥39.7%. Centers operating mostly on complex cases disclosed better outcome including lower post-operative liver failure rates (4% vs 13%; P = 0.002). Centers from Asia disclosed better outcomes. Conclusion: Surgery for PHC remains associated with high morbidity and mortality with now the availability of benchmark values covering 21 outcome parameters, which may serve as key references for comparison in any future analyses of individuals, group of patients or centers.
Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure
Kar, Saibal , Mack, Michael J. , Lindenfeld, JoAnn, Abraham, William T. , Asch, Federico M. , Weissman, Neil J., Enriquez‐Sarano, Maurice , Lim, D. Scott , Mishell, Jacob M. , Rogers, Jason H. , Cohen, David J., Grayburn, Paul , Stone, Gregg W. , Kar, Saibal , Enriquez-Sarano, Maurice , Lim, D Scott , Whisenant, Brian K. , Arnold, Suzanne V. , Cohen, David J.

Mayo Clinic

Circulation | May 27, 2021 | Volume: 144 | Issue: 6 | Pages: 426-437

10.1161/circulationaha.120.053061 | PMID 34039025 Get It

Background: In the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation), among 614 patients with heart failure with 3+ or 4+ secondary mitral regurgitation (MR), transcatheter mitral valve repair (TMVr) with the MitraClip reduced MR, heart failure hospitalizations, and mortality and improved quality of life compared with guideline-directed medical therapy (GDMT) alone. We aimed to examine the prognostic relationship between MR reduction and outcomes after TMVr and GDMT alone. Methods: Outcomes in COAPT between 30 days and 2 years were examined on the basis of the severity of residual MR at 30 days. Results: TMVr-treated patients had less severe residual MR at 30 days than GDMT-treated patients (0/1+, 2+, and 3+/4+: 72.9%, 19.9%, and 7.2% versus 8.2%, 26.1%, and 65.8%, respectively [ P <0.0001]). The rate of composite death or heart failure hospitalizations between 30 days and 2 years was lower in patients with 30-day residual MR of 0/1+ and 2+ compared with patients with 30-day residual MR of 3+/4+ (37.7% versus 49.5% versus 72.2%, respectively [ P <0.0001]). This relationship was consistent in the TMVr and GDMT arms ( P interaction =0.92). The improvement in Kansas City Cardiomyopathy Questionnaire score from baseline to 30 days was maintained between 30 days and 2 years in patients with 30-day MR ≤2+ but deteriorated in those with 30-day MR 3+/4+ (–0.3±1.7 versus –9.4±4.6 [ P =0.0008]) consistently in both groups ( P interaction =0.95). Conclusions: In the COAPT trial, reduced MR at 30 days was associated with greater freedom from death or heart failure hospitalizations and improved quality of life through 2-year follow-up whether the MR reduction was achieved by TMVr or GDMT. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device
Kar, Saibal , Doshi, Shephal K. , Sadhu, Ashish, Horton, Rodney , Osorio, José , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Price, Mathew J., Holmes, David R. , Shipley, Robert D., Gordon, Nicole, Allocco, Dominic J. , Investigators, On behalf of the PINNACLE FLX, Kar, Saibal , Ellis, Christopher R. , Nair, Devi G , Asch, Federico M. , Reddy, Vivek Y. , Investigators, On behalf of the PINNACLE FLX

Mayo Clinic

Circulation | April 6, 2021 | Volume: 143 | Issue: 18 | Pages: 1754-1762

10.1161/circulationaha.120.050117 | PMID 33820423 Get It

Background: Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation. Since regulatory approval in 2015, the WATCHMAN device has been the only LAA closure device available for clinical use in the United States. The PINNACLE FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) evaluated the safety and effectiveness of the next-generation WATCHMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagulation is indicated, but who have an appropriate rationale to seek a nonpharmaceutical alternative. Methods: This was a prospective, nonrandomized, multicenter US Food and Drug Administration study. The primary safety end point was the occurrence of one of the following events within 7 days after the procedure or by hospital discharge, whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure (peri-device flow ≤5 mm), as assessed by the echocardiography core laboratory at 12-month follow-up. Results: A total of 400 patients were enrolled. The mean age was 73.8±8.6 years and the mean CHA 2 DS 2 -VASc score was 4.2±1.5. The incidence of the primary safety end point was 0.5% with a 1-sided 95% upper CI of 1.6%, meeting the performance goal of 4.2% ( P <0.0001). The incidence of the primary effectiveness end point was 100%, with a 1-sided 95% lower CI of 99.1%, again meeting the performance goal of 97.0% ( P <0.0001). Device-related thrombus was reported in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and there were no device embolizations. Conclusions: LAA closure with this next-generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02702271.
Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Gertz, Zachary M. , Herrmann, Howard C. , Lim, D. Scott , Kapadia, Samir , Reed, Grant W. , Puri, Rishi , Krishnaswamy, Amar , Gersh, Bernard J. , Weissman, Neil J., Grayburn, Paul , Redfors, Björn , Zhang, Zixuan , Abraham, William T. , Stone, Gregg W. , Mack, Michael J. , Kapadia, Samir , Herrmann, Howard C , Gersh, Bernard J , Reed, Grant W , Lim, D Scott , Kar, Saibal , Asch, Federico M. , Kosmidou, Ioanna , Lindenfeld, JoAnn

Mayo Clinic

Circulation: Cardiovascular Interventions | March 15, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.010300 | PMID 33719505 Get It

Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
749: Acute Flaccid Paralysis as Initial Presentation of Rapidly Progressive Bacterial Meningitis
Peacock, Sarah , Gassie, Kelly , Bonner, William F., Lee, Seung , Gonzales, Hector Robles, Gunasekera, Charlene L., Siegel, Jason , Peacock, Sarah, Boniface, Michael, Bonner, William

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 371-371

10.1097/01.ccm.0000728884.37141.10 Get It